Market Overview:
The global oral transmucosal drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in oral transmucosal drug delivery devices. Based on type, the global oral transmucosal drugs market is segmented into tablets, films, liquid spray, gels, and others. The tablets segment is expected to account for the largest share of the global oral transmucosal drugs market in 2018. This segment is also projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030 due to its high adoption rate across various applications such as cardiovascular disorders (CVDs), acute pain management (APM), diabetes mellitus (DM), and others. Based on application, the global oral transmucosal drugs market is divided into CVDs, APM,, DM,, and others segments.
Product Definition:
Oral transmucosal drug delivery is the administration of drugs through the oral mucosa. The oral mucosa is a moist and highly vascularized tissue that lines the mouth and throat. It is well suited for drug delivery because it is rich in blood vessels and lymphatic vessels, which allow for rapid absorption of drugs into the bloodstream. The importance of oral transmucosal drug delivery lies in its ability to provide rapid absorption of drugs into the bloodstream, which can result in faster onset of action than traditional oral medications.
Tablets:
Tablets, it's usage.
The global tablets, it’s usage and growth factor in the ORAL TRANSMUCOSAL DRUGS (OTDs) market size was valued at USD 6.1 billion in 2016. It is expected to witness a CAGR of XX% during the forecast period.
Films:
The market for films and its usage in oral transmucosal drugs is expected to grow at a lucrative rate during the forecast period. The growth of this segment can be attributed to factors such as increasing prevalence of cancer, HIV infection, and other chronic diseases coupled with rising demand for novel drug delivery systems.
Application Insights:
The acute pain management segment dominated the global market in 2017. This can be attributed to the increasing number of patients suffering from chronic pains and/or trauma associated with dental, surgical and other injuries. The growing geriatric population is also a key driver for this segment as they are more susceptible to acute pains due to various causes such as musculoskeletal disorders, fractures, sprains and strains.
Accordingly, OTTD drugs used for pain management accounted for a major share in 2017 owing to their easy administration (by mouth) without the need for medical personnel or advanced equipment. Moreover, these drugs exhibit high efficacy compared to conventional analgesics that are traditionally used orally by patients such as tablets & capsules which further boosts their demand worldwide.
Regional Analysis:
Europe dominated the global market in 2017. The presence of well-established healthcare facilities and high adoption of oral transmucosal products are some factors responsible for its large share. In addition, favorable reimbursement policies for OTC drugs and increasing awareness about these therapies are also expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising geriatric population, improving economic conditions, and growing awareness about oral transmucosal products among patients in this region. Moreover, a large number of branded manufacturers have been expanding their business in this region due to low manufacturing cost as compared with developed regions such as North America or Europe which has led it becoming one of the largest revenue-generating regions by 2030’s).
Growth Factors:
- Increasing prevalence of oral diseases: The global prevalence of oral diseases is increasing due to various factors such as unhealthy lifestyles, changing food habits, and increasing population. This is expected to drive the demand for oral transmucosal drugs in the coming years.
- Growing awareness about oral health: There is a growing awareness among people about the importance of oral health and the need for preventive measures against various dental problems. This is expected to boost the demand for Oral Transmucosal Drugs market in the coming years.
- Technological advancements: The Oral Transmucosal Drugs market is witnessing rapid technological advancements, which are helping manufacturers introduce innovative products in this market space. This is likely to fuel growth in this market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oral Transmucosal Drugs Market Research Report
By Type
Tablets, Films, Liquid Spray, Gels, Others
By Application
Cardiovascular Disorders, Acute Pain Managements, Diabetes, Others
By Companies
LTS Lohmann Therapie-Systeme AG, Soligenix, ZIM Laboratories Limited, Access Pharmaceutical Inc., C.L Pharm, Cure Pharmaceutical, Aquestive Therapeutics, Inc., NAL Pharma, IntelGenx Corp., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Viatris, Bristol-Myers Squibb Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
192
Number of Tables & Figures
135
Customization Available
Yes, the report can be customized as per your need.
Global Oral Transmucosal Drugs Market Report Segments:
The global Oral Transmucosal Drugs market is segmented on the basis of:
Types
Tablets, Films, Liquid Spray, Gels, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cardiovascular Disorders, Acute Pain Managements, Diabetes, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- LTS Lohmann Therapie-Systeme AG
- Soligenix
- ZIM Laboratories Limited
- Access Pharmaceutical Inc.
- C.L Pharm
- Cure Pharmaceutical
- Aquestive Therapeutics, Inc.
- NAL Pharma
- IntelGenx Corp.
- Eisai Co., Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Viatris
- Bristol-Myers Squibb Company
Highlights of The Oral Transmucosal Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tablets
- Films
- Liquid Spray
- Gels
- Others
- By Application:
- Cardiovascular Disorders
- Acute Pain Managements
- Diabetes
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oral Transmucosal Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oral transmucosal drugs (OTDs) are medications that are taken by mouth. They are often used to treat conditions such as cancer, HIV/AIDS, and chronic pain. OTDs work by entering the body through the mouth or nose and then working their way to where they're needed.
Some of the major players in the oral transmucosal drugs market are LTS Lohmann Therapie-Systeme AG, Soligenix, ZIM Laboratories Limited, Access Pharmaceutical Inc., C.L Pharm, Cure Pharmaceutical, Aquestive Therapeutics, Inc., NAL Pharma, IntelGenx Corp., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Viatris, Bristol-Myers Squibb Company.
The oral transmucosal drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oral Transmucosal Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oral Transmucosal Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oral Transmucosal Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oral Transmucosal Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oral Transmucosal Drugs Market Size & Forecast, 2020-2028
4.5.1 Oral Transmucosal Drugs Market Size and Y-o-Y Growth
4.5.2 Oral Transmucosal Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Tablets
5.2.2 Films
5.2.3 Liquid Spray
5.2.4 Gels
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Cardiovascular Disorders
6.2.2 Acute Pain Managements
6.2.3 Diabetes
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oral Transmucosal Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oral Transmucosal Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Tablets
9.6.2 Films
9.6.3 Liquid Spray
9.6.4 Gels
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Cardiovascular Disorders
9.10.2 Acute Pain Managements
9.10.3 Diabetes
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Tablets
10.6.2 Films
10.6.3 Liquid Spray
10.6.4 Gels
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Cardiovascular Disorders
10.10.2 Acute Pain Managements
10.10.3 Diabetes
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Tablets
11.6.2 Films
11.6.3 Liquid Spray
11.6.4 Gels
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Cardiovascular Disorders
11.10.2 Acute Pain Managements
11.10.3 Diabetes
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Tablets
12.6.2 Films
12.6.3 Liquid Spray
12.6.4 Gels
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Cardiovascular Disorders
12.10.2 Acute Pain Managements
12.10.3 Diabetes
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Tablets
13.6.2 Films
13.6.3 Liquid Spray
13.6.4 Gels
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Cardiovascular Disorders
13.10.2 Acute Pain Managements
13.10.3 Diabetes
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oral Transmucosal Drugs Market: Competitive Dashboard
14.2 Global Oral Transmucosal Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 LTS Lohmann Therapie-Systeme AG
14.3.2 Soligenix
14.3.3 ZIM Laboratories Limited
14.3.4 Access Pharmaceutical Inc.
14.3.5 C.L Pharm
14.3.6 Cure Pharmaceutical
14.3.7 Aquestive Therapeutics, Inc.
14.3.8 NAL Pharma
14.3.9 IntelGenx Corp.
14.3.10 Eisai Co., Ltd.
14.3.11 Otsuka Pharmaceutical Co., Ltd.
14.3.12 Teva Pharmaceutical Industries Ltd.
14.3.13 GlaxoSmithKline plc
14.3.14 Viatris
14.3.15 Bristol-Myers Squibb Company
